DiscoverNeurology MinuteMonoclonal Antibody to PACAP for Migraine Prevention - Part 2
Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

Update: 2024-09-17
Share

Description

In the second installment of this two-part series, Dr. Tesha Monteith and Dr. Messoud Ashina discuss the results of the phase two study on monoclonal antibody to PACAP for migraine prevention. 

Show reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2314577  

Comments 
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders - Part 1

A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders - Part 1

2024-09-2003:23

CMAP and Myosin-Loss Pathology in Patients With Critical Illness Myopathy

CMAP and Myosin-Loss Pathology in Patients With Critical Illness Myopathy

2024-09-1902:20

Improving Clinical Documentation Efficiency with AI

Improving Clinical Documentation Efficiency with AI

2024-09-1802:50

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

2024-09-1704:30

Depression During Intern Year Increases Risk for Persistent MD Depression: What Can Training Programs Do to Intervene

Depression During Intern Year Increases Risk for Persistent MD Depression: What Can Training Programs Do to Intervene

2024-09-1603:09

Monoclonal Antibody to PACAP for Migraine Prevention - Part 1

Monoclonal Antibody to PACAP for Migraine Prevention - Part 1

2024-09-1305:24

Association of Extent of TSS With Cerebral Glymphatic Clearance in Patients With IIH

Association of Extent of TSS With Cerebral Glymphatic Clearance in Patients With IIH

2024-09-1202:07

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome

2024-09-1101:55

Large Study Finds COVID Vaccination Does Not Increase Multiple Sclerosis Relapses

Large Study Finds COVID Vaccination Does Not Increase Multiple Sclerosis Relapses

2024-09-1002:44

Spinal Muscular Atrophy Update in Best Practices - Part 3

Spinal Muscular Atrophy Update in Best Practices - Part 3

2024-09-0901:33

Specialist Physiotherapy for Functional Motor Disorder

Specialist Physiotherapy for Functional Motor Disorder

2024-09-0601:42

Spinal Muscular Atrophy Update in Best Practices - Part 2

Spinal Muscular Atrophy Update in Best Practices - Part 2

2024-09-0501:59

Spinal Muscular Atrophy Update in Best Practice - Part 1

Spinal Muscular Atrophy Update in Best Practice - Part 1

2024-09-0403:07

Blood Biomarkers to Detect Alzheimer Disease - Part 2

Blood Biomarkers to Detect Alzheimer Disease - Part 2

2024-09-0301:47

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 2

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 2

2024-09-0201:38

Blood Biomarkers to Detect Alzheimer Disease - Part 1

Blood Biomarkers to Detect Alzheimer Disease - Part 1

2024-08-3001:41

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 1

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 1

2024-08-2901:12

New Treatment Option for Parkinson Disease

New Treatment Option for Parkinson Disease

2024-08-2802:33

Chronic Adaptive Deep Brain Stimulation Versus Conventional Stimulation in Parkinson Disease

Chronic Adaptive Deep Brain Stimulation Versus Conventional Stimulation in Parkinson Disease

2024-08-2703:07

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

2024-08-2602:03

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

American Academy of Neurology